STATEMENT OF NEED
Ovarian cancer accounts for 5% of cancer deaths among women in the United States and causes more deaths than any other cancer of the female reproductive system. An estimated 22,240 new cases are diagnosed annually, and 14,070 people die of the disease. Relative survival varies by age; women younger than 65 are much more likely to survive 5 years (77%) following diagnosis than women 65 and older (20%). Overall, the 5-year relative survival rate for ovarian cancer patients is 47%. If diagnosed at the localized stage, the 5-year survival rate is more than 90%; however, only 15% of all cases are detected at this stage, usually incidentally during another medical procedure. Most cases (60%) are diagnosed with distant disease, which is associated with a 5-year survival rate of only 29%.
Gynecologic oncologists, medical oncologists, surgical oncologists, radiation oncologists, pathologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with ovarian cancer.
Upon completion of this activity, participants should be able to:
Ursula A. Matulonis, MD (Chairperson)
Professor of Medicine
Harvard Medical School
Dmitriy Zamarin, MD, PhD
Memorial Sloan Kettering Cancer Center
Shannon N. Westin, MD, MPH
Associate Professor of Gynecologic Oncology
MD Anderson Cancer Center
Melissa Geller, MD, MS
Associate Professor and Division Director, Gynecologic Oncology
University of Minnesota
There is no fee to participate in or claim CME credit for this activity.
Please note that Penn State College of Medicine and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
Jointly Provided by
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and i3 Health. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Relevant financial relationships exist between the following individuals and commercial interests:
Penn State College of Medicine staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
Ursula A Matulonis, MD discloses that she has served as a consultant/advisor for 2X Oncology, Clearity Foundation, FujiFilm, Geneos, Merck, Myriad Genetics. She has also received a research grant from Merck.
Dmitriy Zamarin, MD, PhD discloses that he has served as consultant/advisor for BioMed Valley Discoveries, Merck, PsiOxus Therapeutics, and Synlogic Therapeutics. He has also received a research grant from Merck.
Shannon N. Westin, MD, MPH discloses that she has served as a consultant/advisor for AstraZeneca, Bayer, Clovis, Genentech Roche, Medivation, Merck, Ovation, Pfizer, and Tesaro. She has also received research grants from AstraZeneca, Bayer, Clovis, Cotinga, Genentech, Novartis, and Tesaro.
Melissa Geller, MD, MS discloses that she has received research grants from Fate Therapeutics, Genentech, Morphotek, and Tesaro.
UNAPPROVED USE DISCLOSURE
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
This activity is supported by an independent educational grant from AstraZeneca and TESARO.
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Penn State College of Medicine, i3 Health, or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.